U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS
This repository is under review for potential modification in compliance with Administration directives.

Showing 1 - 10 of 168 results

Status:
US Approved Rx (2024)
First approved in 2024

Class (Stereo):
CHEMICAL (ACHIRAL)



Xanomeline (LY-246,708) is an orthosteric muscarinic acetylcholine receptor (mAChR) agonist, often referred to as M1/M4-preferring. It is also known to act as a M5 receptor antagonist. Xanomeline was studied in clinical trials phase I in schizophreni...
Status:
US Approved Rx (2018)
First approved in 2018

Class (Stereo):
CHEMICAL (ACHIRAL)



Revefenacin (trade name Yupelri is a long-acting muscarinic antagonist developed by Mylan Ireland ltd for the treatment of chronic obstructive pulmonary disease (COPD). It has similar affinity to the subtypes of muscarinic receptors M1 to M5. In the...
Status:
US Approved Rx (2017)
First approved in 2008

Class (Stereo):
CHEMICAL (ABSOLUTE)



Fesoterodine (trade name Toviaz) is a prodrug of 5-hydroxymethyl tolterodine, which is also the active metabolite of tolterodine. Fesoterodine and its active metabolites are nonsubtype selective, competitive antagonists of human muscarinic receptors...
Status:
US Approved Rx (2019)
First approved in 2004

Class (Stereo):
CHEMICAL (ABSOLUTE)



Solifenacin is a competitive muscarinic acetylcholine receptor antagonist. The binding of acetylcholine to these receptors, particularly the M3 receptor subtype, plays a critical role in the contraction of smooth muscle. By preventing the binding of ...
Status:
US Approved Rx (2000)
First approved in 2000

Class (Stereo):
CHEMICAL (RACEMIC)



Cevimeline is a cholinergic agonist, which binds to muscarinic receptors. Muscarinic agonists in sufficient dosage can increase secretion of exocrine glands, such as salivary and sweat glands and increase tone of the smooth muscle in the gastrointest...
Status:
US Approved Rx (2001)
First approved in 1986

Class (Stereo):
CHEMICAL (RACEMIC)



Ipratropium (ipratropium bromide, ATROVENT® HFA) is a muscarinic antagonist structurally related to atropine but often considered safer and more effective for inhalation use. It is indicated for the maintenance treatment of bronchospasm associated wi...
Status:
US Approved Rx (2008)
First approved in 1979

Class (Stereo):
CHEMICAL (ACHIRAL)



Metoclopramide is a dopamine D2 antagonist that is used as an antiemetic. Metoclopramide inhibits gastric smooth muscle relaxation produced by dopamine, therefore increasing cholinergic response of the gastrointestinal smooth muscle. It accelerates i...
Status:
US Approved Rx (2018)
First approved in 1975

Class (Stereo):
CHEMICAL (RACEMIC)



Oxybutynin is an antispasmodic, anticholinergic agent indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and frequency. Oxybutynin relaxes bladder smooth muscle. Oxybutynin exhibits only one-fifth o...
Status:
US Approved Rx (1988)
First approved in 1975

Class (Stereo):
CHEMICAL (ACHIRAL)



Loxapine is a dibenzoxazepine tricyclic antipsychotic agent, available for oral and inhalatory administration, classified as a typical antipsychotic. Loxapine acts as an antagonist at central serotonin and dopamine receptors. Adasuve (loxapine inhala...
Status:
US Approved Rx (2009)
First approved in 1961

Class (Stereo):
CHEMICAL (RACEMIC)



Glycopyrrolate is a synthetic anticholinergic agent with a quaternary ammonium structure. Glycopyrrolate is a muscarinic competitive antagonist used as an antispasmodic, in some disorders of the gastrointestinal tract, and to reduce salivation with s...